The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $1.14

Today's change0.00 0.00%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $1.14

Today's change0.00 0.00%
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc unchanged

Infinity Pharmaceuticals Inc is unchanged Friday sitting at (U.S.)$1.14. Over the last five days, shares have lost 8.80% and are down 15.56% for the last year to date. This security has underperformed the S&P 500 by 37.51% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $1.14
  • High--
  • Low--
  • Bid / Ask(U.S.) $1.22 / (U.S.) $1.23
  • YTD % change-15.56%
  • Volume83,163
  • Average volume (10-day)908,448
  • Average volume (1-month)1,060,211
  • Average volume (3-month)643,438
  • 52-week range(U.S.) $0.84 to (U.S.) $3.84
  • Beta2.57
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.39
Updated September 22 4:00 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue0000
Total other revenue--------
Total revenue0000
Gross profit--------
Total cost of revenue--------
Total operating expense10102320
Selling / general / administrative6697
Research & development441513
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-10-10-23-20
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-17-10-23-19
Income after tax-17-10-23-19
Income tax, total----00
Net income-17-10-23-19
Total adjustments to net income--------
Net income before extra. items-17-10-23-19
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-17-10-23-19
Inc. avail. to common incl. extra. items-17-10-23-19
Diluted net income-17-10-23-19
Dilution adjustment--------
Diluted weighted average shares50505050
Diluted EPS excluding extraordinary itemsvalue per share-0.34-0.21-0.46-0.39
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.34-0.21-0.46-0.39